Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE. Knappskog S, et al. Among authors: mjaaland i. Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8. Mol Oncol. 2015. PMID: 26004085 Free PMC article.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. Meattini I, et al. Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. Lancet Oncol. 2024. PMID: 38301705 Review.
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Kaidar-Person O, et al. Among authors: mjaaland i. Radiother Oncol. 2023 Dec 19:110060. doi: 10.1016/j.radonc.2023.110060. Online ahead of print. Radiother Oncol. 2023. PMID: 38122852 Free article. Review.
Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases - an open, multicentre, randomised non-inferiority phase 3 trial.
Alkner S, de Boniface J, Lundstedt D, Mjaaland I, Ryden L, Vikstrom J, Bendahl PO, Holmberg E, Sackey H, Wieslander E, Karlsson P. Alkner S, et al. Among authors: mjaaland i. BMJ Open. 2023 Sep 26;13(9):e075543. doi: 10.1136/bmjopen-2023-075543. BMJ Open. 2023. PMID: 37751948 Free PMC article.
Coping After Breast Cancer: Protocol for a Randomized Controlled Trial of Stress Management eHealth Interventions.
Svendsen K, Nes LS, Meland A, Larsson IM, Gjelsvik YM, Børøsund E, Rygg CM, Myklebust TÅ, Reinertsen KV, Kiserud CE, Skjerven H, Antoni MH, Chalder T, Mjaaland I, Carlson LE, Eriksen HR, Ursin G. Svendsen K, et al. Among authors: mjaaland i. JMIR Res Protoc. 2023 May 24;12:e47195. doi: 10.2196/47195. JMIR Res Protoc. 2023. PMID: 37103493 Free PMC article.
Clinical oncology module for the ESTRO core curriculum.
Benstead K, Lara PC, Eller Y, Engell-Noerregaard L, Eriksen JG, Gaye PM, Jaal J, Juretic A, Kase M, Kouloulias V, Kozma E, Lagerlund M, Lumsden G, Meattini I, Mjaaland I, Pfeffer R. Benstead K, et al. Among authors: mjaaland i. Radiother Oncol. 2021 Mar;156:19-22. doi: 10.1016/j.radonc.2020.11.029. Epub 2020 Dec 1. Radiother Oncol. 2021. PMID: 33276018
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.
Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H. Helland T, et al. Among authors: mjaaland i. Mol Oncol. 2021 Apr;15(4):957-967. doi: 10.1002/1878-0261.12865. Epub 2020 Dec 14. Mol Oncol. 2021. PMID: 33252186 Free PMC article.
50 results